Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06386198Recruiting
Health Advocate for Young Liver Transplant Patients
This study tests a program that helps young adults with a liver transplant prepare to move from a children’s hospital to an adult hospital. It aims to provide extra support for people who also have social needs like trouble getting enough food.
San Francisco, CaliforniaAges 18–25 - NCT07637578RecruitingPhase 2
Elranatamab infusions for relapsed or refractory myeloma
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
Denver, ColoradoAges 18 years+ - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Atlanta, GeorgiaAges 50 years+ - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT06310551RecruitingPhase 1
Long-acting HIV prevention study for healthy adults
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
Lenexa, KansasAges 18–55 - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Birmingham, AlabamaAges 18–75 - NCT07088068RecruitingPhase 3
Teplizumab for newly diagnosed type 1 diabetes
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
Scottsdale, ArizonaAges 1–25 - NCT07483346RecruitingPhase 1
Testing IASO-782 for systemic lupus erythematosus
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06262789Recruiting
Returning to work after blood cancer treatment
This study helps people who have finished treatment for a blood cancer (like leukemia or lymphoma) figure out the best way to return to work. It looks at what support might be needed during this transition.
AngersAges 18–55 - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT06805656RecruitingPhase 2
Trial to reduce HIV reservoirs aiming for treatment-free remission
This study tests whether a combination approach, including a drug called nicotinamide (a form of vitamin B3) and other strategies, can reduce the hidden HIV reservoir enough to allow a temporary pause in antiretroviral therapy without the virus rebounding. It is for people who have well-controlled HIV and strong immune systems.
São Paulo, São PauloAges 18–65 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
New Haven, ConnecticutAges 18–55 - NCT06351488Recruiting
Detecting kidney DNA to spot organ rejection early
This study looks for pieces of kidney DNA in the blood of people who have a kidney transplant and need a biopsy. The goal is to see if this test can help doctors know if the kidney is being rejected without needing a biopsy.
ParisAges 18 years+ - NCT06820281RecruitingPhase 2
Tirzepatide for type 1 diabetes: a metabolism study
This study tests if tirzepatide, a medicine that helps lower blood sugar and manage weight, is safe and effective for people with type 1 diabetes who are overweight or have obesity. You must already use an automated insulin pump system.
Sydney, New South WalesAges 18–65 - NCT07665307Recruiting
Delayed side effects after CAR-T for multiple myeloma
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
San Francisco, CaliforniaAges 18 years+ - NCT07495631Recruiting
Chemo + venetoclax + immunotherapy for adult ALL
This trial combines a kid-inspired chemotherapy backbone with a targeted pill (venetoclax) and immunotherapy (special antibodies) to treat adults with Ph-negative acute lymphoblastic leukemia (ALL). The goal is to use a more effective, less toxic approach developed for children.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07739654RecruitingPhase 3
Modified chemotherapy combo for relapsed large b-cell lymphoma
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Lahore, Punjab ProvinceAges 18 years+ - NCT07038746RecruitingPhase 1
Inhaled epinephrine for severe allergic reactions during tests or treatment
This trial tests if inhaled epinephrine can safely treat moderate to severe allergic reactions (grade 2 or higher) that can happen during allergy skin tests, oral food or drug challenges, or allergy shots. It is for people who have had such reactions in the past or are at risk and are planning to undergo one of these procedures.
Richmond, British ColumbiaAges 12 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.